Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

X. Roblin · SciRah

Researcher profile · Semantic Scholar

X. Roblin

Share profile

X. Roblin — researcher profile on SciRah

h-index: 56
Works: 466
Citations: 11K

Most-cited papers

Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
K. Papamichael, W. Afif, D. Drobne, M. Dubinsky +18 more
2022The Lancet Gastroenterology and Hepatology107 citations Open access
Semantic Scholar
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
L. Peyrin-Biroulet, J. Allegretti, D. Rubin, B. Bressler +159 more
2023Gastroenterology91 citations Open access
Semantic Scholar
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
E. Louis, M. Resche-Rigon, D. Laharie, J. Satsangi +47 more
2023The Lancet Gastroenterology and Hepatology76 citations Open access
Semantic Scholar
Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer
A. Lavelle, S. Nancey, J. Reimund, D. Laharie +16 more
2022Gut microbes55 citations Open access
Semantic Scholar
Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn’s disease
Gregoire Chevalier, Arnaud Laveissière, G. Desachy, N. Barnich +29 more
2021Microbiome55 citations Open access
Semantic Scholar
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
L. Peyrin-Biroulet, P. Arkkila, A. Armuzzi, S. Danese +12 more
2022BMC Gastroenterology51 citations Open access
Semantic Scholar
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
A. Buisson, S. Nancey, L. Manlay, D. Rubin +9 more
2021United European Gastroenterology journal47 citations Open access
Semantic Scholar
Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease.
X. Roblin, S. Nancey, K. Papamichael, G. Duru +6 more
2023Journal of Crohn's & Colitis41 citations
Semantic Scholar
Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study.
A. Buisson, M. Serrero, L. Orsat, S. Nancey +21 more
2022Inflammatory Bowel Diseases37 citations
Semantic Scholar
Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms.
B. Ungar, K. Malíčková, J. Hanžel, Muhammad Abu Arisha +18 more
2021Journal of Crohn's & Colitis34 citations
Semantic Scholar
Subcutaneous injection of infliximab CT‐P13 results in stable drug levels within 14‐day treatment cycle in Crohn’s disease
X. Roblin, P. Veyrard, L. Bastide, A. Berger +7 more
2022Alimentary Pharmacology and Therapeutics27 citations
Semantic Scholar
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study
M. Fumery, A. Defrance, X. Roblin, R. Altwegg +21 more
2022Alimentary Pharmacology and Therapeutics27 citations
Semantic Scholar
Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study
Niels Vande Casteele, W. Sandborn, B. Feagan, S. Vermeire +11 more
2022Alimentary Pharmacology and Therapeutics26 citations Open access
Semantic Scholar
Corticosteroids and 5-ASA versus corticosteroids for acute severe ulcerative colitis: A randomized controlled trial.
S. Ben-Horin, O. Har-Noy, K. Katsanos, X. Roblin +17 more
2022Clinical Gastroenterology and Hepatology25 citations Open access
Semantic Scholar
Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis.
P. Veyrard, G. Pellet, D. Laharie, M. Nachury +2 more
2022Clinical Gastroenterology and Hepatology23 citations Open access
Semantic Scholar
Genetic Diagnosis Guides Treatment of Autoimmune Enteropathy
F. Charbit-Henrion, Manon Haas, S. Chaussade, C. Cellier +35 more
2022Clinical Gastroenterology and Hepatology23 citations Open access
Semantic Scholar
Alteration of microbiota antibody‐mediated immune selection contributes to dysbiosis in inflammatory bowel diseases
Eva Michaud, L. Waeckel, Rémi Gayet, Roman Goguyer-Deschaumes +11 more
2022EMBO Molecular Medicine23 citations Open access
Semantic Scholar
Use of imaging modalities for decision-making in inflammatory bowel disease
S. Nancey, M. Fumery, M. Faure, G. Boschetti +3 more
2023Therapeutic Advances in Gastroenterology22 citations Open access
Semantic Scholar
Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAID.
C. Reenaers, A. de Roover, L. Kohnen, M. Nachury +23 more
2021Inflammatory Bowel Diseases21 citations Open access
Semantic Scholar
Determinants of IBD‐related disability: a cross‐sectional survey from the GETAID
J. Tannoury, M. Nachury, Carole Martins, M. Serrero +21 more
2021Alimentary Pharmacology and Therapeutics20 citations Open access
Semantic Scholar
OP14 Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO
G. D'Haens, C. Taxonera, A. López-Sanromán, P. N. Mateu +13 more
2023Journal of Crohn's & Colitis19 citations Open access
Semantic Scholar
Adalimumab in biologic-naïve patients with Crohn's disease after resolution of an intra-abdominal abscess: a prospective study from the GETAID.
Y. Bouhnik, G. D. de Chambrun, J. Lambert, M. Nachury +23 more
2023Clinical Gastroenterology and Hepatology18 citations Open access
Semantic Scholar
Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study
A. Meyer, M. Fumery, L. Peyrin-Biroulet, J. Filippi +21 more
2022Scandinavian Journal of Gastroenterology16 citations
Semantic Scholar
Prevalence and determinants of fatigue in patients with IBD: a cross-sectional survey from the GETAID.
A. Amiot, Sayma Chaibi, Y. Bouhnik, M. Serrero +28 more
2023Journal of Crohn's & Colitis15 citations Open access
Semantic Scholar
Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease
X. Roblin, G. Duru, K. Papamichael, A. Cheifetz +6 more
2023Journal of Clinical Medicine14 citations Open access
Semantic Scholar
Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10® to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies
A. Berger, A. Gleizes, L. Waeckel, X. Roblin +4 more
2022International Journal of Molecular Sciences14 citations Open access
Semantic Scholar
A Systematic Review on the interest of Drug Tolerant assay in the monitoring of Inflammatory Bowel Disease.
M. Barrau, M. Duprat, P. Veyrard, Q. Tournier +7 more
2022Journal of Crohn's & Colitis13 citations
Semantic Scholar
Physical Activity and IBD: State of Art and Knowledge, Patients and Healthcare Professionals Points of View, A French Multicenter Cross Sectional Study.
L. Derbey, A. Charlois, A. Buisson, X. Roblin +5 more
2024Inflammatory Bowel Diseases12 citations
Semantic Scholar
Essential role of TOSO/FAIM3 in intestinal IgM reverse transcytosis.
N. Rochereau, Eva Michaud, L. Waeckel, M. Killian +6 more
2021Cell Reports12 citations Open access
Semantic Scholar
Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn’s Disease
F. Veyre, G. Boschetti, C. Meunier, C. Cuerq +11 more
2021Digestive Diseases and Sciences12 citations
Semantic Scholar
Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID
G. Boschetti, M. Nachury, D. Laharie, X. Roblin +17 more
2022American Journal of Gastroenterology11 citations Open access
Semantic Scholar
Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab.
Rachel Porth, T. Deyhim, Samantha Zullow, L. Rabinowitz +5 more
2024Inflammatory Bowel Diseases10 citations
Semantic Scholar
Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study
L. Sirmai, A. Pelletier, N. Gault, C. Zallot +11 more
2022World Journal of Gastroenterology10 citations Open access
Semantic Scholar
Early venous thromboembolism is a strong prognostic factor in patients with advanced pancreatic ductal adenocarcinoma
M. Barrau, K. Maoui, B. Le Roy, X. Roblin +3 more
2021Journal of Cancer Research and Clinical Oncology10 citations Open access
Semantic Scholar
Prevalence of the Oral Corticosteroid Exposure and Excessive Use in Patients with Inflammatory Bowel Disease: Data from Four French Referral Centers of the International DICE Study
S. Nancey, X. Hébuterne, C. Gilletta, Evguenia Hacques +1 more
2024Journal of Clinical Medicine8 citations Open access
Semantic Scholar
Prevalence of and factors associated with extraintestinal manifestations and their remission in inflammatory bowel disease: the EXTRA prospective study from the GETAID.
L. Guillo, G. Savoye, A. Amiot, C. Gilletta +20 more
2023Clinical and Translational Gastroenterology8 citations Open access
Semantic Scholar
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
L. Peyrin-Biroulet, P. Arkkila, A. Armuzzi, S. Danese +13 more
2024BMC Gastroenterology7 citations Open access
Semantic Scholar
Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID.
R. Al Bacha, Y. Bouhnik, M. Serrero, J. Filippi +21 more
2023Digestive and Liver Disease7 citations Open access
Semantic Scholar
Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study
M. Fumery, S. Nancey, J. Filippi, R. Altwegg +6 more
2023Alimentary Pharmacology and Therapeutics7 citations
Semantic Scholar
What Should We Know about Drug Levels and Therapeutic Drug Monitoring during Pregnancy and Breastfeeding in Inflammatory Bowel Disease under Biologic Therapy?
M. Barrau, X. Roblin, L. Andromaque, A. Rozières +3 more
2023Journal of Clinical Medicine7 citations Open access
Semantic Scholar
Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study.
S. Vieujean, D. Laharie, A. Buisson, X. Roblin +7 more
2023Digestive and Liver Disease7 citations Open access
Semantic Scholar
Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study
L. Guillo, A. Amiot, M. Serrero, R. Altwegg +44 more
2022Digestive Diseases and Sciences7 citations Open access
Semantic Scholar
Serum calprotectin is useful to confirm Inflammatory Bowel Disease activity but not to predict relapse
P. Veyrard, X. Roblin, C. Pansart, R. Mao +9 more
2022Clinical Immunology Communications6 citations Open access
Semantic Scholar
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
A. Albshesh, L. Bannon, Tali Sharar Fischler, M. Truyens +14 more
2023Journal of Clinical Medicine5 citations Open access
Semantic Scholar
Therapeutic Drug Monitoring for Subcutaneous Infliximab? Too early to conclude.
E. Loftus, S. Paul, X. Roblin
2023Clinical Gastroenterology and Hepatology5 citations
Semantic Scholar
Relationships of circulating CD4+ T cell subsets and cytokines with the risk of relapse in patients with Crohn’s disease
R. Duclaux-Loras, G. Boschetti, B. Flourié, X. Roblin +16 more
2022Frontiers in Immunology5 citations Open access
Semantic Scholar
Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.
R. Little, Adrian Swaine, R. Reynolds, D. J. Gibson +7 more
2023Inflammatory Bowel Diseases4 citations
Semantic Scholar
Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn’s disease and is responsive to filgotinib
W. Reinisch, A. Serone, X. Hébuterne, T. Kühbacher +10 more
2022Tissue Barriers4 citations Open access
Semantic Scholar
DOP85 Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn’s Disease and inadequate response to risankizumab maintenance therapy
F. Baert, R. Atreya, Y. Kakuta, M. Long +8 more
2022Journal of Crohn's & Colitis4 citations Open access
Semantic Scholar
Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study
Taku Kobayashi, A. Dignass, X. Roblin, Y. Takatori +4 more
2024Intestinal Research3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Nancey×25
Invite
S. Nancey — researcher profile on SciRah
L. Peyrin-Biroulet×17
Invite
L. Peyrin-Biroulet — researcher profile on SciRah
D. Laharie×16
Invite
D. Laharie — researcher profile on SciRah
M. Nachury×14
Invite
M. Nachury — researcher profile on SciRah

×13

Invite

A. Buisson — researcher profile on SciRah

Invite

R. Altwegg — researcher profile on SciRah

C. Gilletta×12

Invite

C. Gilletta — researcher profile on SciRah

Invite

L. Vuitton — researcher profile on SciRah

Invite

M. Fumery — researcher profile on SciRah

X. Hébuterne×10

Invite

X. Hébuterne — researcher profile on SciRah

Invite

M. Serrero — researcher profile on SciRah

Invite

S. Viennot — researcher profile on SciRah